DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Commercial Interests at AACR 2017 - A 1stOncology Insights Report" report to their offering.
This report is a unique guide to understanding and evaluating the positions of the cancer drugs and companies presented at the AACR 2017 Annual Meeting.
This leading event in the oncology drug developers calendar represents some of the very best in cancer science and this report allows the reader to review the meeting through the lens of 17 hot areas in oncology. As such, it is a must read for anyone with an interest in oncology and who wants a full picture of the landscape of drug development emerging from AACR 2017.
With more than 6,500+ abstracts presented at AACR 2017, this report allows you to break down this mountain of information to reveal the positions of the more than 470 commercial drugs with published abstracts by their own innovating companies or partners.
These drugs represent the core of what is happening in cancer drug development today and this report reveals where they are positioned in 17 "hot" areas in oncology, including:
- Fierce 15 Drugs
- Orphan Drugs
- Breakthrough Therapies
- Cancer Vaccines
- CAR/TCR Therapies
- Immune Checkpoints
- Epigenetic Therapies
- Protein Kinase Inhibitors
- Antibodies in Oncology
- Cancer Peptides
- Nucleic Acid Therapies
- Conjugated Drugs
The AACR Annual Meeting is one of the events that shapes the direction of commercial drug development in oncology. Use this report to understand from a trustworthy third-party the position, strengths, weaknesses and recent successes and failures of the drugs represented at this years meeting in an executive and easy to understand format.
Key Topics Covered:
1 Executive Summary
2 About 1stOncology Insights
3 Table of Contents
4 Major Recent Developments on Cancer Drugs at AACR from 2016 to Present
5 Overview of Cancer Drugs at AACR 2017
6 AACR 2017 by Startups
7 AACR 2017 by Fierce 15 Companies
8 AACR 2017 by Orphan Drugs
9 AACR 2017 by Breakthrough Therapies
10 AACR 2017 by Cancer Vaccines
11 AACR 2017 by CAR/TCR Therapies
12 AACR 2017 by Immune Checkpoint Drugs
13 AACR 2017 by Epigenetic Therapies
14 AACR 2017 by DNA Damage Response Drugs
15 AACR 2017 by Protein Kinase Inhibitors
16 AACR 2017 by Antibody Drugs
17 AACR 2017 by Peptide Drugs
18 AACR 2017 by Nucleic Acid Therapies
19 AACR 2017 by Conjugated Drugs
21 Drug Index
22 Drug Innovator Index
For more information about this report visit http://www.researchandmarkets.com/research/qvrhd4/commercial